Work

A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer

Year: 2026

Type: article

Abstract: Objectives To evaluate the diagnostic value of multimodal MRI by comprising quantitative mapping, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced MRI (DCE-MRI) in differentiating triple-negative breast cancer (TNBC) from non-TNBC, and to investigate the correlation between significant quantitative mapping parameters and the Ki-67 proliferation index. Methods This prospective study enrolled 120 patients with invasive breast cancer (30 TNBC and 90 non-TNBC) who underwent preoperative quantitative mapping, DWI, and DCE-MRI. DCE-MRI parameters (RE, ME, MRE, T0, TTP, WI, WO, BOE), DWI metrics (ADCmin, ADCmean, rADCmin, rADCmean), and quantitative mapping parameters (Native T1, Enhanced T1, ΔT1, ΔT1%, T2) were compared between groups. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC) for both individual significant parameters and a combined predictive model. Pearson’ s correlation coefficient was used to analyze the relationship between quantitative mapping parameters and the Ki-67 index. Results Compared to the non-TNBC group, TNBC lesions exhibited significantly lower RE, ME, WI, WO, and ΔT1% ( p < 0.05), but higher Enhanced T1 and T2 values ( p < 0.05). The combined model integrating DCE-MRI and quantitative mapping achieved the highest diagnostic accuracy (AUC = 0.977), outperforming DCE-MRI alone (AUC = 0.951) and quantitative mapping alone (AUC = 0.864), with sensitivity and specificity of 93.3% and 92.2%, respectively. In TNBC, the Ki-67 index showed a weak positive correlation with Enhanced T1 (r = 0.387, p < 0.05) and T2 (r = 0.381, p < 0.05). Conclusion Parameters including RE, ME, WI, WO, Enhanced T1, ΔT1%, and T2 serve as valuable imaging biomarkers for the preoperative identification of TNBC. Integrating quantitative mapping with DCE-MRI significantly enhances diagnostic performance, offering a robust approach for differentiating TNBC from non-TNBC subtypes.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2026.1714620